Key facts
- It has raised $36.4M across 2 recorded rounds; the latest was Early Stage VC ($8.4M) in Dec 2023.
- Notable investors include ARUP Laboratories, Atomic (Private Equity), University of Utah, Zoetis.
- Techcyte has filed 2 Form Ds with the SEC since 2021, most recently Jan 2024 ($8.4M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Techcyte
Funding rounds
2 roundsAbout Techcyte
Developer of a first cloud-based digital pathology platform designed to support both anatomic and clinical pathology. The company's platform consists of workflow and AI (Artificial Intelligence) to help labs with the efficiency and accuracy of their diagnostic testing, its technology uses deep learning image analysis and is HIPAA compliant, CE marked, enabling support tests across histology, hematology, cytology, bacteriology, and parasitology, providing human, veterinary, and environmental clinics and labs with AI-powered digital diagnostics tools.
- Sector
- Healthcare
- HQ
- Orem, UT, United States
- Founded
- 2013
- Employees
- 155
- Website
- techcyte.com/
- Ownership
- Privately Held (backing)
Techcyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Techcyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Techcyte in its N-PORT filings yet. We sweep new filings monthly.